UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
13
April 2026 - “Transactions in Own Shares”
|
99.1
Haleon plc: Aggregated
information - transactions in own shares
13 April 2026: Haleon
plc (the "Company" or "Haleon") today announces the
purchase of 7,740,513 ordinary shares of £0.01 each in the
Company (the "Shares") for cancellation under
its share buyback programme announced on 12 March
2026.
|
|
London Stock Exchange
|
CBOE (UK)/BXE
|
CBOE (UK)/CXE
|
Aquis
|
|
Date of purchase:
|
7 April 2026
|
|||
|
Number of Shares purchased:
|
888,210
|
615,286
|
787,828
|
-
|
|
Highest price paid per Share (p):
|
376.1000
|
376.0000
|
376.0000
|
-
|
|
Lowest price paid per Share (p):
|
367.5000
|
367.6000
|
367.5000
|
-
|
|
Volume weighted average price paid per Share (p):
|
371.5015
|
371.3255
|
371.6528
|
-
|
|
Date of purchase:
|
8 April 2026
|
|||
|
Number of Shares purchased:
|
995,159
|
509,180
|
495,387
|
-
|
|
Highest price paid per Share (p):
|
375.0000
|
372.0000
|
372.0000
|
-
|
|
Lowest price paid per Share (p):
|
368.2000
|
368.3000
|
368.3000
|
-
|
|
Volume weighted average price paid per Share (p):
|
370.4762
|
370.2369
|
370.4203
|
-
|
|
Date of purchase:
|
9 April 2026
|
|||
|
Number of Shares purchased:
|
1,583,132
|
911,974
|
497,143
|
-
|
|
Highest price paid per Share (p):
|
366.4000
|
366.4000
|
366.4000
|
-
|
|
Lowest price paid per Share (p):
|
361.6000
|
361.6000
|
362.4000
|
-
|
|
Volume weighted average price paid per Share (p):
|
363.1091
|
363.0479
|
363.6388
|
-
|
|
Date of purchase:
|
10 April 2026
|
|||
|
Number of Shares purchased:
|
194,408
|
115,163
|
147,643
|
-
|
|
Highest price paid per Share (p):
|
367.2000
|
367.2000
|
367.2000
|
-
|
|
Lowest price paid per Share (p):
|
364.8000
|
364.8000
|
364.8000
|
-
|
|
Volume weighted average price paid per Share (p):
|
366.2767
|
366.1567
|
366.1972
|
-
|
Following the settlement of the above, the Company's registered
share capital is
8,919,824,040 ordinary shares of £0.01 each, of
which 12,439,998 are held as treasury shares. Therefore,
the number of ordinary shares with voting rights is 8,907,384,042
and this
figure may be used by shareholders to determine if they are
required to notify their interest, or a change to their interest,
in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014
as it applies in the UK (the Market Abuse Regulation), a
full breakdown of the individual trades is available at the link
below:
This announcement does not constitute, or form part of, an offer or
any solicitation of an offer for securities in any
jurisdiction.
This announcement and individual trade breakdown will also be
available on the Company's website at: www.haleon.com/investors.
|
Enquiries
|
|
||
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
April 13, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|